Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

Tamura, K; Tsurutani, J; Takahashi, S; Iwata, H; Krop, IE; Redfern, C; Sagara, Y; Doi, T; Park, H; Murthy, RK; Redman, RA; Jikoh, T; Lee, C; Sugihara, M; Shahidi, J; Yver, A; Modi, S

Tamura, K (reprint author), Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo 1040045, Japan.

LANCET ONCOLOGY, 2019; 20 (6): 816

Abstract

Background Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody-drug conjugate with a humanised anti-H ER2 antibody, cleavable peptide-......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索